CORONADO, Calif. (EGMN) - Eighty percent of patients whose non-small cell lung cancer (NSCLC) stopped responding to gefitinib had a response or stabilization of their disease when they were retreated with gefitinib at a later time in a small, ongoing phase II trial."This study suggests that even if we have progression, some sensitive cells remain, and it may be worth going back on gefitinib after failure of [intervening] chemotherapy," said lead investigator Dr. In-Jae Oh in an interview conducted...